login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EXAGEN INC (XGN) Stock News
USA
- NASDAQ:XGN -
US30068X1037
-
Common Stock
9.61
USD
+0.05 (+0.52%)
Last: 11/10/2025, 11:39:01 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
XGN Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Chartmill
Exagen Inc. (NASDAQ:XGN) Reports Mixed Q3 2025 Results with Revenue Beat and Wider-Than-Expected Loss
6 days ago - By: Zacks Investment Research
- Mentions:
FTLF
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
6 days ago - By: Exagen Inc.
Exagen Inc. Reports Strong Q3 2025 Results
6 days ago - By: Exagen Inc.
Exagen Inc. Reports Strong Q3 2025 Results
6 days ago - By: Benzinga
- Mentions:
KURA
SEE
HRMY
FOLD
...
Earnings Scheduled For November 4, 2025
14 days ago - By: Benzinga
- Mentions:
CRS
EL
RNA
GKOS
...
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
18 days ago - By: Exagen Inc.
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
18 days ago - By: Exagen Inc.
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
20 days ago - By: Exagen Inc.
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
20 days ago - By: Exagen Inc.
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
3 months ago - By: Exagen Inc.
Exagen Inc. to Participate in Third Quarter Investor Conferences
3 months ago - By: Exagen Inc.
Exagen Inc. to Participate in Third Quarter Investor Conferences
3 months ago - By: The Motley Fool
Exagen Q2 Revenue Jumps 14 Percent
3 months ago - By: Zacks Investment Research
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: Exagen Inc.
Exagen Inc. Reports Strong Q2 2025 Results
3 months ago - By: Exagen Inc.
Exagen Inc. Reports Strong Q2 2025 Results
4 months ago - By: Yahoo Finance
Exagen Inc. (XGN): A Bull Case Theory
4 months ago - By: Exagen Inc.
Exagen Inc. Appoints Chas McKhann to Board of Directors
4 months ago - By: Exagen Inc.
Exagen Inc. Appoints Chas McKhann to Board of Directors
4 months ago - By: Exagen Inc.
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
4 months ago - By: Exagen Inc.
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
5 months ago - By: Exagen Inc.
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
5 months ago - By: Exagen Inc.
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
6 months ago - By: Exagen Inc.
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
6 months ago - By: Exagen Inc.
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
6 months ago - By: Exagen Inc.
Exagen Inc. Prices Public Offering of Common Stock
6 months ago - By: Exagen Inc.
Exagen Inc. Prices Public Offering of Common Stock
6 months ago - By: Exagen Inc.
Exagen Inc. Announces Proposed Public Offering of Common Stock
6 months ago - By: Exagen Inc.
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
Please enable JavaScript to continue using this application.